following a full submission:
nivolumab, relatlimab (Opdualag®) is accepted for use within NHSScotland.
Indication under review: first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older.
In a randomised, double-blind, phase II/III study of adults with previously untreated advanced melanoma, nivolumab-relatlimab fixed-dose combination was associated with a statistically significant improvement in progression-free survival when compared with a single-agent immunotherapy.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- nivolumab / relatlimab (Opdualag)
- SMC ID:
- SMC2645
- Indication:
For treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and over.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 08 July 2024